Show simple item record

dc.contributor.authorGonzalez-Perez, Maria 
dc.contributor.authorMontes-Casado, Maria 
dc.contributor.authorConde-San Román, Patricia 
dc.contributor.authorCervera Hernandez, Isabel 
dc.contributor.authorBaranda Prellezo, Jana 
dc.contributor.authorBerges-Buxeda, Marcos Joaquín 
dc.contributor.authorPerez-Olmeda, Mayte 
dc.contributor.authorSanchez-Tarjuelo, Rodrigo 
dc.contributor.authorUtrero-Rico, Alberto
dc.contributor.authorLozano-Ojalvo, Daniel
dc.contributor.authorTorre, Denis
dc.contributor.authorSchwarz, Megan
dc.contributor.authorGuccione, Ernesto
dc.contributor.authorCamara, Carmen
dc.contributor.authorLlópez-Carratalá, M Rosario
dc.contributor.authorGonzalez-Parra, Emilio
dc.contributor.authorPortoles, Pilar 
dc.contributor.authorOrtiz, Alberto
dc.contributor.authorPortoles, Jose
dc.contributor.authorCano-Ochando, Jordi
dc.identifier.citationFront Immunol. 2022 Mar 23;13:845882.es_ES
dc.description.abstractLong-term hemodialysis (HD) patients are considered vulnerable and at high-risk of developing severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection due to their immunocompromised condition. Since COVID-19 associated mortality rates are higher in HD patients, vaccination is critical to protect them. The response towards vaccination against COVID-19 in HD patients is still uncertain and, in particular the cellular immune response is not fully understood. We monitored the humoral and cellular immune responses by analysis of the serological responses and Spike-specific cellular immunity in COVID-19-recovered and naïve HD patients in a longitudinal study shortly after vaccination to determine the protective effects of 1273-mRNA vaccination against SARS-CoV-2 in these high-risk patients. In naïve HD patients, the cellular immune response measured by IL-2 and IFN-ɣ secretion needed a second vaccine dose to significantly increase, with a similar pattern for the humoral response. In contrast, COVID-19 recovered HD patients developed a potent and rapid cellular and humoral immune response after the first vaccine dose. Interestingly, when comparing COVID-19 recovered healthy volunteers (HV), previously vaccinated with BNT162b2 vaccine to HD patients vaccinated with 1273-mRNA, these exhibited a more robust immune response that is maintained longitudinally. Our results indicate that HD patients develop strong cellular and humoral immune responses to 1273-mRNA vaccination and argue in favor of personalized immune monitoring studies in HD patients, especially if COVID-19 pre-exposed, to adapt COVID-19 vaccination protocols for this immunocompromised population.es_ES
dc.description.sponsorshipFunding was obtained from Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS2040 (RD21/0005/0001), FEDER funds; Acción Estratégica en Salud Intramural (AESI), Instituto de Salud Carlos III, grant number AESI PI21CIII_00022 to PP and Healthstar-plus -REACT-UE Grant through Segovia Arana Research Institute Puerta de Hierro Majadahonda-IDIPHIM. JO is a member of VACCELERATE (European Corona Vaccine Trial Accelerator Platform) Network, which aims to facilitate and accelerate the design and implementation of COVID-19 phase 2 and 3 vaccine trials. JO is a member of the INsTRuCT under the MSC grant agreement Nº860003 (Innovative Training in Myeloid Regulatory Cell Therapy) Consortium, a network of European scientists from academia and industry focused on developing innovative immunotherapies.es_ES
dc.publisherFrontiers Media es_ES
dc.subjectSARS-CoV-2 vaccinees_ES
dc.subjectCellular responsees_ES
dc.subjectChronic kidney diseasees_ES
dc.subjectHumoral responsees_ES
dc.subject.meshCOVID-19 Vaccineses_ES
dc.subject.meshAntibodies, Viral es_ES
dc.subject.meshBNT162 Vaccinees_ES
dc.subject.meshHumans es_ES
dc.subject.meshImmunity, Humoral es_ES
dc.subject.meshLongitudinal Studies es_ES
dc.subject.meshRNA, Messenger es_ES
dc.subject.meshRenal Dialysis es_ES
dc.subject.meshVaccination es_ES
dc.titleDevelopment of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccinationes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderFundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda es_ES
dc.identifier.journalFrontiers in Immunologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto
Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional